SEEKER is the first and only platform in newborn screening for lysosomal storage disorders authorized by the FDA!
SEEKER is a high throughput laboratory solution that quantitatively measures the activity of lysosomal enzymes from newborn dried blood spot specimens. Reduced activity of these enzymes may be indicative of Mucopolysaccharidosis Type I (MPS I), Pompe, Gaucher or Fabry disease.
SEEKER is designed for ease of use, minimal maintenance and flexible future expansion.
Each SEEKER cartridge contains 48 wells for specimens, calibrators and quality control samples. Dried blood spot samples are extracted from a 96-well plate and the extracts from one plate are transferred to two SEEKER cartridges.
With the capability of multiple runs per day and the abundance of hands off time using SEEKER, average throughput per day is 960 samples*.
*Assumes 2 SEEKER workstations (8 SEEKER instruments), 3 runs per day
(40 samples x 4 instruments per workstation x 2 workstations x 3 runs = 960 total samples)
“FDA clearance enables state laboratories to confidently implement testing while minimizing the validation effort resulting in a cost effective implementation.”Bradford Therrell, Jr., PhD,
Director of the National Newborn Screening and Global Resource Center